The acquisition is complete and Pacira shares will be delisted. PCRX holders who did not tender will receive $36.50 per share in the merger. Monitor any appraisal litigation or disclosure-related lawsuits disclosed in the SC 14D-9/A, though these are unlikely to affect the deal's consummation.
PCRX drugs
PCRX drug pipeline →Price Chart
Executive Summary
Viatris completed its acquisition of Pacira BioSciences via a tender offer and subsequent merger. The tender offer expired on November 16, 2026, with 32,929,780 shares (66.46%) validly tendered. All conditions were satisfied, and on November 17, 2026, Purchaser accepted the shares for payment at $36.50 per share in cash, and the merger was consummated, making Pacira a wholly owned subsidiary of Viatris. The shares will be delisted from Nasdaq.
Key Financial Metrics
Key Facts
- Tender offer expired Nov 16, 2026; 32,929,780 shares (66.46%) validly tendered
- Offer price: $36.50 per share in cash
- All conditions satisfied or waived on Nov 17, 2026
- Purchaser accepted all validly tendered shares and consummated merger on Nov 17, 2026
- Merger completed under Section 251(h) of DGCL without stockholder vote
- Shares to be delisted from Nasdaq Global Select Market
- Viatris expects acquisition to contribute $90M-$100M in total revenues for remainder of 2026 (Nov 17 - Dec 31, 2026)
- Cross-filing context: SC 14D-9/A (Nov 12) disclosed stockholder lawsuits and demand letters challenging disclosure adequacy; board continues to recommend offer
Financial Impact
All-cash deal at $36.50 per share; total consideration based on ~49.5M shares outstanding (implied by 66.46% = 32.93M shares) is approximately $1.8B. Viatris expects $90M-$100M revenue contribution from Pacira for Nov 17 - Dec 31, 2026.
Risk Factors
- Stockholder lawsuits and demand letters challenging disclosure adequacy in the merger (disclosed in SC 14D-9/A filed Nov 12, 2026)
- Potential appraisal claims by shareholders who properly demanded appraisal under DGCL Section 262
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC TO-T/A Filing (Primary) | 0001140361-26-044347 |
| Document: ny20085362x2_exa5e.htm | 0001140361-26-044347 |
| Document: 0001140361-26-044347-index-headers.html | 0001140361-26-044347 |
| Document: 0001140361-26-044347-index.html | 0001140361-26-044347 |
| Document: 0001140361-26-044347.txt | 0001140361-26-044347 |
Track record
33 reports on PCRX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 17, 20264d ago 8-K Mixed 8/10 Entry $36.48 Now $36.48 −0.00% settles Dec 16
- Nov 17, 20264d ago SC 14D-9/A Mixed 8/10 Entry $36.48 Now $36.48 −0.00% settles Dec 16
- Nov 17, 20264d ago SC TO-T/A Mixed 7/10 Viewing Entry $36.48 Now $36.48 −0.00% settles Dec 16
- Nov 17, 20264d ago 25-NSE Neutral 1/10 Entry $36.48 Now $36.48 −0.00% settles Dec 16
- Nov 12, 20269d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
- Nov 12, 20269d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 12, 20269d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 5, 202616d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
- Nov 3, 202618d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
- Oct 30, 202622d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers